Clinical Trials on Blood Coagulation Tests in South Africa

Total 4709 results

Catalyst Biosciences

Completed

Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B

Hemophilia B

South Africa
Baxalta now part of Shire

Terminated

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A

Hemophilia A

United States, South Africa, United Kingdom
Bayer

Completed

Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors (MATCHBOX)

Hemophilia A | Hemophilia B

South Africa, Poland, United Kingdom
Novo Nordisk A/S

Completed

Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries (HAEMOcare)

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia B

India, Morocco, South Africa, Oman
Vega Therapeutics, Inc

Recruiting

Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease

Von Willebrand Diseases

United States, Austria, South Africa, United Kingdom
BioMarin Pharmaceutical

Active, not recruiting

Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5 (GENEr8-AAV5+)

Hemophilia A | Gene Therapy | Blood Disorder | Clotting Disorders

Taiwan, Korea, Republic of, United Kingdom, South Africa
Catalyst Biosciences

Completed

Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

Armenia, Georgia, South Africa, Poland, Russian Federation
Laboratoire français de Fractionnement et de Biotechnologies
LFB USA, Inc.

Completed

LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures (PerSept3)

Hemophilia

United States, Ukraine, Mexico, Russian Federation, South Africa, Spain
Pfizer

Completed

PF-06741086 Multiple Dose Study in Severe Hemophilia

Hemophilia A or B

United States, Chile, Croatia, Poland, South Africa, Switzerland
Medexus Pharma, Inc.

Completed

Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B

Hemophilia B

Turkey, Brazil, Georgia, Moldova, Republic of, South Africa, Ukraine
Laboratoire français de Fractionnement et de Biotechnologies
LFB USA, Inc.

Completed

A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (PERSEPT2)

Hemophilia A With Inhibitors | Hemophilia B With Inhibitors

Bulgaria, Ukraine, Czechia, United States, Georgia, South Africa
Pfizer

Completed

PF-06741086 Long-term Treatment in Severe Hemophilia

Hemophilia A or B

Poland, Switzerland, South Africa, United States, Croatia, Brazil, Chile
CSL Behring

Terminated

Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors

Hemophilia A With Inhibitors | Hemophilia B With Inhibitors

Georgia, Italy, Malaysia, Russian Federation, South Africa, Spain, Thailand, Ukraine, United Kingdom
Christian Medical College, Vellore, India

Unknown

Musculoskeletal Function in Hemophilia

Hemophilia

India, Argentina, Brazil, Egypt, Iran, Islamic Republic of, Singapore, South Africa, Thailand, Venezuela
BioMarin Pharmaceutical

Recruiting

Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors (GENEr8-INH)

Hemophilia A With Inhibitor | Hemophilia A With Anti Factor VIII

United States, United Kingdom, Taiwan, Israel, Korea, Republic of, South Africa, Brazil, Italy, Germany
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors (HAVEN 2)

Hemophilia A

United States, France, Germany, Italy, South Africa, Spain, Turkey, Japan, United Kingdom, Costa Rica
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors (HAVEN 3)

Hemophilia A

Australia, Taiwan, Korea, Republic of, France, Germany, Italy, South Africa, Spain, United States, Japan, Ireland, Poland, United Kingdom, Costa Rica
Laboratoire français de Fractionnement et de Biotechnologies

Recruiting

A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM (SCOPE HIM)

Hemophilia

United States, Thailand, Malaysia, Mexico, Turkey, South Africa
Octapharma

Completed

Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery (WONDERS)

Prevent Bleeding in Major Surgery

United States, Turkey, Romania, India, Bulgaria, Italy, Oman, Poland, South Africa
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B (Kids B-LONG)

Hemophilia B

United States, United Kingdom, South Africa, Netherlands, Ireland, Australia
Catalyst Biosciences

Completed

Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia

Hemophilia A

United States, Belgium, Hungary, Italy, New Zealand, South Africa, Turkey, United Kingdom
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors (HAVEN 1)

Hemophilia A

Korea, Republic of, United States, France, Germany, Italy, South Africa, Spain, Japan, United Kingdom, Poland, Taiwan, Australia, Costa Rica, New Zealand
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Terminated

BAX 802 in CHA With Inhibitors (CHAWI)

Hemophilia A

Netherlands, Spain, Italy, Turkey, Bulgaria, United States, Canada, Germany, Norway, Poland, Russian Federation, South Africa
Hoffmann-La Roche

Completed

A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment

Hemophilia A

United States, Korea, Republic of, Italy, South Africa, Spain, China, Japan, Poland, Australia, Costa Rica, Germany, Taiwan
Novo Nordisk A/S

Completed

Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B (Explorer 1)

Healthy | Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

Austria, Sweden, Spain, Switzerland, United Kingdom, Germany, Malaysia, Denmark, South Africa, Thailand, Italy
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A (Kids ALONG)

Hemophilia A

United States, Poland, United Kingdom, Netherlands, South Africa, Hong Kong, Australia, Ireland
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors (HAVEN 7)

Severe Hemophilia A

Canada, United States, United Kingdom, Belgium, Australia, Austria, Brazil, France, Germany, Israel, Italy, South Africa, Spain, Turkey
Novo Nordisk A/S

Completed

A Research Study Investigating Mim8 in People With Haemophilia A (FRONTIER1)

Healthy Volunteers | Haemophilia A With or Without Inhibitors

United States, Germany, Spain, Austria, Bulgaria, Italy, Japan, South Africa, Switzerland, Turkey, United Kingdom, Poland
Novo Nordisk A/S

Active, not recruiting

A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5) (FRONTIER 5)

Haemophilia A With Inhibitors | Haemophilia A

Spain, Korea, Republic of, Canada, United Kingdom, United States, Germany, South Africa, Italy, Austria, Belgium, France, Japan
GlaxoSmithKline

Completed

Study to Determine the Bioequivalence of Two Fixed Dose Combination (FDC) Tablet Formulations of Amlodipine and Losartan FDC5/50 and FDC5/100 Under Fasting Conditions

Hypertension

South Africa
University of Witwatersrand, South Africa

Completed

Comparison Of Trabeculectomy Versus The Ex-PRESS Miniature Glaucoma Device In The Same Patient: A Prospective Randomized Study (XVT-USF)

Glaucoma

South Africa
Spark Therapeutics
Children's Hospital of Philadelphia; University of Pittsburgh; St. James's Hospital... and other collaborators

Terminated

Hemophilia B Gene Therapy With AAV8 Vector

Hemophilia B

United States, Australia
Freeline Therapeutics

Terminated

A Long-Term Follow-Up Study of Haemophilia B Patients Who Have Undergone Gene Therapy

Hemophilia B

United Kingdom
GlaxoSmithKline

Completed

Bioequivalence Study Between GSK3542503 Hydrochlorothiazide + Amiloride Hydrochloride 50 mg: 5 mg Tablets and Reference Product in Healthy Adult Participants Under Fasting Conditions

Hypertension

South Africa
ApcinteX Ltd
Centessa Pharmaceuticals plc

Recruiting

The Efficacy and Safety of SerpinPC in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B (PRESent-2)

Hemophilia A | Hemophilia B

United States, Italy, Spain, Taiwan, Australia, Belgium, United Kingdom, France, Germany, India, South Africa, Poland, Canada, Armenia, Turkey
Ocular Therapeutix, Inc.

Completed

Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment of Subjects With Open Angle Glaucoma

Glaucoma

South Africa
ApcinteX Ltd
Centessa Pharmaceuticals plc

Recruiting

Hemophilia Non-Interventional Study Prior to SerpinPC Intervention (PRESent-5)

Hemophilia A | Hemophilia B

Spain, Taiwan, United Kingdom, Italy, Germany, United States, South Africa, Australia, Egypt, Poland, Armenia, France, India, Canada, Brazil, Turkey
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B

Severe Hemophilia B

Sweden, United States, France, Italy, Russian Federation, United Kingdom, Germany, China, Poland, Japan, Australia, Brazil, Canada, India, South Africa, Hong Kong, Belgium
Novo Nordisk A/S

Completed

Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients

Trauma | Acquired Bleeding Disorder

Germany, Austria, Israel, France, Canada, Singapore, South Africa, Australia, United Kingdom
Fondazione Angelo Bianchi Bonomi
Sintesi Research Srl

Completed

Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET)

Hemophilia A

United States, India, Spain, Argentina, Austria, Brazil, Chile, Egypt, Iran, Islamic Republic of, Italy, Mexico, Saudi Arabia, South Africa, Turkey
IDinsight
Reach Digital Health (formerly Praekelt.org)

Recruiting

Testing Content Delivery Models for MomConnect (MQR)

Hematological Diseases | Breastfeeding | Immunization Coverage

South Africa
Bayer

Completed

BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)

Hemophilia A | Hematologic Disease

France, Italy, Spain, United States, United Kingdom
Freeline Therapeutics

Completed

AAV Gene Therapy Screening/Observational Protocol (ECLIPSE) (ECLIPSE)

Hemophilia B | Blood Coagulation Disorders, Inherited | Blood Coagulation Disorder | Haematologic Disease

United States, United Kingdom, Australia, Netherlands, Austria, France, Ireland, Italy, Turkey, Canada, Germany, South Africa
University of Johannesburg

Completed

The Effect of a Homoeopathic Complex on Blood Pressure in Refractory Hypertension

Essential Hypertension

South Africa
Pfizer

Completed

A Gene Therapy Study for Hemophilia B

Hemophilia B

United States, Australia
University of Johannesburg

Completed

Venavine Intensive® in the Treatment of Symptoms Associated With Chronic Venous Insufficiency

Venous Insufficiency

South Africa
Novo Nordisk A/S

Completed

Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors (ONE)

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

Saudi Arabia, Algeria, Turkey, Germany, Poland, Netherlands, Italy, Belgium, South Africa, United Kingdom, Sweden, Austria, Portugal, France, Czech Republic, Venezuela
CSL Behring

Completed

A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

Hemophilia B

United States, Australia, Japan, France, Philippines, Spain, Czechia, Israel, Canada, Germany, Austria, Bulgaria, Italy, Malaysia, South Africa
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors (HAVEN 6)

Hemophilia A | Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor | Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor

United States, Netherlands, Belgium, France, Germany, South Africa, Spain, Canada, United Kingdom, Poland
Nova Laboratories Limited

Completed

Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions

Acute Lymphoblastic Leukemia

South Africa

Clinical Trials on Blood Coagulation Tests in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations